REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
281.62
-2.56 (-0.90%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close283.33
Open283.84
Bid274.36 x 800
Ask284.50 x 1000
Day's Range279.50 - 286.95
52 Week Range271.57 - 442.00
Volume617,113
Avg. Volume769,961
Market Cap30.931B
Beta (3Y Monthly)0.86
PE Ratio (TTM)15.64
EPS (TTM)18.00
Earnings DateNov 4, 2019 - Nov 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est386.33
Trade prices are not sourced from all markets
  • 3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector
    InvestorPlace

    3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector

    On the stump, if there's one thing that both Republican and Democratic politicians have long claimed to support, it's lower drug prices. And when rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed…some fairly, and some not (as we'll see).That's just what happened in the past week.House Speaker Nancy Pelosi has a tougher proposal on her agenda than, say, President Trump. While the Trump administration is more interested in importing lower-priced versions of the drugs from Canada, Pelosi wants to apply direct pressure to pharmaceutical companies.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSpecifically, Pelosi wants to allow the Dept. of Health & Human Services to negotiate prices for Medicare Part D drug plans directly with drug manufacturers. (That would, effectively, eject pharmacy benefit managers and insurance companies from the negotiating table.)Several biotech stocks have taken big hits on the regulatory rumors. Some of the Big Pharma crowd even showed up on the list of three-year lows last week! Let's review - because while some deserve to be sold, one big mover is actually on my Top 5 Stocks list for Breakthrough Stocks. * 7 Discount Retail Stocks to Buy for a Recession First we have Biogen (NASDAQ:BIIB), a potential target of Pelosi's proposal. With its famously pricey drug for spinal muscular atrophy, Spiranza, Biogen may well come into Democrats' crosshairs here. BIIB stock dropped sharply last Friday and again on Thursday.You may think that with pricing like $750,000 for your first year of Spiranza, Biogen would be printing money. But Spiranza just picked up a competitor from Novartis (NYSE:NVS). And below is the full picture on BIIB stock from my Portfolio Grader:While Biogen passes some of my profitability tests, it gets an F for Earnings Momentum, and Sales Growth is lackluster as well. Most concerning is the fact that BIIB stock got a D for its Quantitative Grade - my proprietary measure of institutional buying pressure.Regeneron Pharmaceuticals (NASDAQ:REGN) is looking even worse. The stock got off to a rough start this week, and while it's clawed back somewhat, it's still down 8% in the past month. For its part, Regeneron has a cholesterol drug (Praluent) that was so expensive that it eventually succumbed to pressure, reduced prices by 60%, and yet it still costs $5,850 a year.Here's REGN's Report Card:As you see above, Regeneron just does not measure up on Operating Margin Growth, Earnings Growth, Earnings Momentum or its Quantitative Grade.Then there's Repligen (NASDAQ:RGEN). While it may have a similar name and ticker, RGEN has much stronger fundamentals. Shares took an even bigger hit - but this is a much more interesting case.Repligen is a unique biotech: This company actually has no drugs of its own, but rather, its products are used in drug manufacturing.Repligen hit the biotechnology scene back in 1981, as it started to develop Protein A ligands to aid in the production of biologic treatments. The company has expanded rapidly since then, and was even named one of the Top 100 fastest-growing companies in the U.S. in 2018. Today, along with Protein A ligands, Repligen offers several products and solutions to enhance the production of biologic drugs.Strong demand for Repligen's biologic solutions was apparent in the company's second-quarter earnings report. The company reported 48% annual revenue growth and 121.4% annual earnings growth. Plus, second-quarter earnings of $0.31 per share crushed estimates for $0.25 per share by 24%.Given the strong second-quarter results, analysts have increased full-year 2019 forecasts in the past two months. Analysts are forecasting 32.9% annual earnings growth and 37.1% annual sales growth.This all makes for a very impressive Report Card on RGEN, as you see here:So, when this kind of stock drops as hard as RGEN just did, I view it as a chance to pick up shares at "bargain basement" prices for a great, long-term play. There's Something Else That Sets These Breakthrough Stocks ApartIf you take a look at RGEN stock, you'll notice its much smaller market cap of $4 billion, versus giant biotech stocks like BIIB and REGN with $30 billion (or more)!If you're a growth investor - and I certainly am; I've made my career this way - then you've got to look at elite small-caps like this. With growth statistics like RGEN's (and my other Breakthrough Stocks), the sky is the limit.RGEN is 4 on my list of Top 5 Stocks. To get my buy price - and the rest of the list - check out Breakthrough Stocks now. When you do, you'll learn all about my "Quantum A" system for identifying the best small-cap investments.Ultimately, spotting the right investment is simple. You buy when the company achieves a Quantum A …and you sell when it disappears.You don't fall in love. You certainly don't fall for hype. You may return to that stock someday - but with my system, you know exactly when it's time to take profits off the table.That's why I always say: There's no luck and very little skill behind my own success - just hard work. And the result: a proprietary system for picking the best investments of the day. It's made it easy to nab market-beating returns - for double your money (or better).I'm eager to show you what my system is picking up now. Click here to find out more.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Big IPO Stocks From 2019 to Watch * 7 Discount Retail Stocks to Buy for a Recession * 7 Stocks to Buy Benefiting From Millennial Money The post 3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector appeared first on InvestorPlace.

  • Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use
    Zacks

    Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use

    Glaxo's (GSK) asthma medicine, Nucala gets FDA approval for use in pediatric patient population.

  • Adverum Reports Data From Phase I Wet AMD Study, Stock Down
    Zacks

    Adverum Reports Data From Phase I Wet AMD Study, Stock Down

    Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.

  • Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe
    Zacks

    Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe

    The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.

  • GuruFocus.com

    Stocks That Fell to 3-Year Lows in the Week of Sept. 6

    Biogen Inc. (BIIB), Regeneron Pharmaceuticals Inc. (REGN), Canon Inc. (CAJ) and Annaly Capital Management Inc. (NLY) have declined to their respective three-year lows Continue reading...

  • Regeneron (REGN) Down 5.2% Since Last Earnings Report: Can It Rebound?
    Zacks

    Regeneron (REGN) Down 5.2% Since Last Earnings Report: Can It Rebound?

    Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
    Zacks

    Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More

    Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.

  • Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study
    Zacks

    Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study

    A combination regimen of Esperion (ESPR) and Merck's Zetia significantly improves bad cholesterol (LDL-C) levels in patients with both hypercholesterolemia and type II diabetes.

  • How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support
    Investor's Business Daily

    How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support

    The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.

  • Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court
    Zacks

    Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court

    Regeneron (REGN) and partner Sanofi get a favorable ruling against Amgen in the ongoing litigation of Praluent.

  • Benzinga

    The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 28) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down ...

  • PR Newswire

    U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced today that the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen's asserted patent claims for antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) are invalid based on lack of enablement. "Today's decision by the U.S. District Court for the District of Delaware validates our position that Amgen's patents are overly broad and invalid," said Joseph LaRosa, Executive Vice President, General Counsel and Secretary, Regeneron.

  • U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
    Reuters

    U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

    The ruling from U.S. District Judge Richard Andrews in Wilmington, Delaware was the latest reversal of fortune in a long-running lawsuit in which Amgen is seeking to stop French drugmaker Sanofi and U.S. biotech Regeneron from selling their drug Praluent. Repatha and Praluent won U.S. approval about two weeks apart in July of 2016.

  • Reuters

    UPDATE 3-U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

    A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug. The ruling from U.S. District Judge Richard Andrews in Wilmington, Delaware was the latest reversal of fortune in a long-running lawsuit in which Amgen is seeking to stop French drugmaker Sanofi and U.S. biotech Regeneron from selling their drug Praluent.

  • Barrons.com

    Amgen Faces Trouble in the Anti-Cholesterol-Drug Battle, Analyst Says

    A newer technology that uses small-interfering RNA to the same effect might serve a major blow to the anti-cholesterol antibodies, including Amgen ’s Repatha.

  • American City Business Journals

    The region's largest construction project is taking shape on Regeneron's campus

    The project is part of the $800 million manufacturing complex Regeneron is constructing on 130 acres off Tempel Lane in East Greenbush that is visible to the 46,400 cars and trucks that travel along Interstate 90 through Rensselaer County every day.

  • Inovio (INO) Down More Than 30% in 3 Months: Here's Why
    Zacks

    Inovio (INO) Down More Than 30% in 3 Months: Here's Why

    Inovio (INO) stops the development of INO-5401 for advanced bladder cancer, and cuts workforce by 28% and annual burn rate by 25% as part of the restructuring process.

  • Esperion's Drugs in Review Hold Potential, Funds a Concern
    Zacks

    Esperion's Drugs in Review Hold Potential, Funds a Concern

    Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo therapy seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize launch.

  • Read This Before You Buy Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Because Of Its P/E Ratio
    Simply Wall St.

    Read This Before You Buy Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Because Of Its P/E Ratio

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll show...

  • Bill Nygren Drills Into Permian Basin Oil
    GuruFocus.com

    Bill Nygren Drills Into Permian Basin Oil

    Guru establishes 3 new positions in 2nd quarter Continue reading...

  • The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
    Zacks

    The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron

    The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron

  • The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier
    Zacks

    The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier

    The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier

  • Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
    Zacks

    Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More

    Key highlights of the past week include drug approvals, and other regulatory and pipeline news.

  • Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100
    Zacks

    Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100

    Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.

  • Here's Why AnaptysBio Shares Are Slipping Today
    Motley Fool

    Here's Why AnaptysBio Shares Are Slipping Today

    An executive's departure at a sensitive time has investors nervous.